The Scott and White Memorial Hospital, Scott, Sherwood and Brindley Foundation and the Scott and White Clinic provide comprehensive, high quality health care for a 49 county area in Central Texas. Since the early 1900s, the Scott and White institution has demonstrated leadership in providing innovative cancer care emphasized by medical education and research. Continuing with this tradition of quality care for the community, Scott and White is pursuing NIH funding of the Community Clinical Oncology Program (CCOP) to support these objectives. The proposed CCOP consists of the hospital and clinic components at Scott and White, as well as, the Central Texas Veterans Health Care System as an affiliate. The proposed research bases will include the Southwest Oncology Group, the National Surgical Breast and Bowel Project, MD Anderson Cancer Center, the Childrens Oncology Group, and Eastern Cooperative Oncology Group. The components and the affiliate will continue to work together in promoting innovative cooperative group studies in the community and contributing to quality research through refinement of processes to identify patients for protocol enrollment. The objectives for the CCOP will be to further support the commitment to delivering research options to the community that include cancer control, prevention, and treatment studies. The CCOP will continue to build on the existing strategies to recruit minority participants onto NCI-sponsored protocols by establishing relationships with ethnic community leaders; through outreach activities; and by providing access to services in underserved areas. The disease-specific teams which were developed to expedite patient discussion and treatment plan decisions, will continue to improve processes with a patient-centered approach to treatment. Community-based involvement will be strengthened by increasing participation in cancer-related organizations that support the goal of eradicating life-threatening cancers through education, research, and providing access for underserved areas. A consistent growth in the Central Texas area, increased health plan participation and the expansion of outreach clinics has placed an increasing demand for cancer services at Scott and White. As a result, the CCOP is expecting an increasing patient accrual onto research protocols. Funding by the NIH will enable Scott and White to continue as the recognized leader in cancer research and treatment for the Central Texas community.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA074647-08
Application #
6777501
Study Section
Special Emphasis Panel (ZCA1-SRRB-E (J1))
Program Officer
O'Mara, Ann M
Project Start
1997-08-01
Project End
2008-05-31
Budget Start
2004-06-01
Budget End
2005-05-31
Support Year
8
Fiscal Year
2004
Total Cost
$443,531
Indirect Cost
Name
Scott and White Memorial Hospital
Department
Type
DUNS #
076697960
City
Temple
State
TX
Country
United States
Zip Code
76504
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Erba, Harry P; Othus, Megan; Walter, Roland B et al. (2014) Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. Leuk Res 38:329-33
Bepler, Gerold; Zinner, Ralph G; Moon, James et al. (2014) A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer 120:2343-51
Smerage, Jeffrey B; Barlow, William E; Hortobagyi, Gabriel N et al. (2014) Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32:3483-9

Showing the most recent 10 out of 97 publications